Archives of Gynaecology and Women Health

Abstract

Background: Female Sexual Dysfunction (FSD) is a multifactorial condition reported to affect a substantial proportion of wom en, with limited approved therapeutic options.

Proposal: This paper proposes a hypothesis-driven, over-the-counter nutraceutical combination intended to address several proposed mechanisms relevant to FSD and outlines a translational research pathway in silico, preclinical, and Phase II clinical to test that hypothesis. No combined formulation of these eight ingredients has been tested to date; the synergy described here is a research hypothesis, not an established finding.

Methods: A narrative review identified eight nutraceuticals with individual-ingredient evidence plausibly relevant to FSD mechanisms: Resveratrol, Ashwagandha, Tribulus terrestris, L-Arginine, Black Cohosh, Evening Primrose Oil, Shilajit, and Visnadine. Proposed outcomes: If the proposed research program is carried out, it may clarify whether combined administration affects vasodilation, hormonal measures, oxidative stress markers, and patient-reported sexual function outcomes. These are hypothesized endpoints, not demonstrated results.

Conclusion: A multi-mechanism nutraceutical approach to FSD is a reasonable hypothesis worth testing given the individual-ingredient evidence base, but currently rests on inference from single-ingredient studies rather than combination data.

Introduction

Female Sexual Dysfunction: Overview:

Female Sexual Dysfunction (FSD) encompasses a spectrum of conditions, including:

• Hypoactive Sexual Desire Disorder (HSDD)

• Female Sexual Arousal Disorder (FSAD)

• Female Orgasmic Disorder (FOD)

Current Treatment Landscape

Existing pharmacological interventions are commonly characterized by:

• A limited number of FDA-approved options

• Reported side effects such as nausea and hypotension

• Accessibility and adherence challenges for some patients.

Nutraceutical Rationale

Nutraceuticals are proposed here as a complementary avenue worth investigating, on the basis that they may offer:

• Multi-mechanistic biological activity, based on individual-ingredient studies

• A generally reported favorable safety profile relative to some prescription options, though this has not been tested for this combination

• Over-the-counter accessibility

2. Nutraceutical Selection and Mechanistic Rationale

Table 1: summarizes the eight candidate ingredients, their proposed mechanisms, and the supporting source identified for each, following independent verification of each citation.

Proposed Synergistic Rationale [Speculation — not tested as a combination]

Vasodilation pathway:  L-Arginine + Resveratrol + Visnadine are hypothesized to support genital blood flow.

Hormonal/stress pathway: Ashwagandha (cortisol) + Black Cohosh (phytoestrogenic activity) are hypothesized to support desire and reduce discomfort.

Antioxidant pathway: Evening Primrose Oil + Shilajit are hypothesized to reduce oxidative stress markers.

Androgen/energy pathway: Tribulus + Shilajit are hypothesized to support subjective energy and arousal

Table 2: Proposed Pathway Integration

3. Research Hypothesis

Hypothesis: a combination of the ingredients above may improve FSD-related symptoms via one or more of the following mechanisms, relative to placebo:

• Increased genital blood flow

• Changes in sex hormone and stress hormone measures

• Reduced oxidative stress markers

• Changes in neurotransmitter-linked subjective measures (desire, arousal)

This is a hypothesis to be tested, not a demonstrated effect of the combination.

4. Proposed Methodology

1. Preliminary Investigations

i) In silico phase: 

• Molecular docking studies

• Systems-biology pathway modeling

ii) Preclinical studies:

• In vitro mechanism validation

• Ovariectomized rat model investigations

2. Proposed Clinical Trial Design:

Proposed Phase II trial parameters:

• Double-blind, placebo-controlled design

• 12-week duration

• Approximately 200 participants (to be confirmed by a formal power calculation)

• Outcome measures: Female Sexual Function Index (FSFI) scores, hormonal panels, patient-reported outcomes

5. Anticipated Outcomes and Significance

1. Primary Outcomes (hypothesized, not observed)

• A meaningful improvement in FSFI scores, magnitude to be determined by the trial rather than assumed in advance

• Change in oxidative stress markers

• Change in relevant hormonal measures

2. Potential Public Health Relevance

• Addresses a condition reported to affect a substantial share of women, pending confirmation of the specific prevalence figure used

• May reduce some access barriers associated with prescription-only treatments, if shown safe and effective

• Would offer an additional option alongside, not a replacement for, existing clinical care

6. Challenges and Limitations

1. Bioavailability:

• Nano-encapsulation and dosage optimization may be needed to reach physiologically relevant tissue concentrations

2. Study limitations:

• Individual variability in response

• FSD is a multifactorial condition; a single formulation is unlikely to address every contributing cause

• No combination data yet exist for these eight ingredients together; single-ingredient evidence does not establish combined efficacy or safety

• Several of the source studies used here measured outcomes (bone density, cortisol, hot flashes) other than sexual function directly, which limits how directly they support FSD-specific claims

Conclusion

This proposal outlines a multi-mechanism nutraceutical strategy for FSD, grounded in individual-ingredient evidence of varying strength and directness. Whether the combination improves FSD outcomes, and whether it does so more safely or effectively than existing options, has not been tested and should be treated as an open research question rather than a settled conclusion.

References

1. Evans, Hamish M., Peter RC Howe, and Rachel HX Wong. "Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women; a 14-week randomised placebo-controlled intervention trial." Nutrients 9, no. 1 (2017): 27.
   View at Publisher | View at Google Scholar
2. Chandrasekhar, Kartik, Jyoti Kapoor, and Sridhar Anishetty. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian Journal of Psychological Medicine 34, no. 3 (2012): 255-262.
   View at Publisher | View at Google Scholar
3. Akhtari, Elham, Firoozeh Raisi, Mansoor Keshavarz, Hamed Hosseini, Farnaz Sohrabvand, Soodabeh Bioos, Mohammad Kamalinejad, and Ali Ghobadi. "Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo-controlled study." DARU Journal of Pharmaceutical Sciences 22, no. 1 (2014): 1-7.
   View at Publisher | View at Google Scholar
4. Cieri-Hutcherson, Nicole E., Andrea Jaenecke, Ajeet Bahia, Debra Lucas, Ann Oluloro, Lora Stimmel, and Timothy C. Hutcherson. "Systematic review of L-arginine for the treatment of hypoactive sexual desire disorder and related conditions in women." Pharmacy 9, no. 2 (2021): 71.
   View at Publisher | View at Google Scholar
5. Shams, Taghreed, Maninder Singh Setia, Robert Hemmings, Jane McCusker, Maida Sewitch, and Antonio Ciampi. "Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis." Alternative Therapies in Health & Medicine 16, no. 1 (2010): 36.
   View at Publisher | View at Google Scholar
6. Farzaneh, Farah, Setareh Fatehi, Mohammad-Reza Sohrabi, and Kamyab Alizadeh. "The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial." Archives of Gynecology and Obstetrics 288, no. 5 (2013): 1075-1079.
   View at Publisher | View at Google Scholar
7. Pingali, Usharani, and Chandrasekhar Nutalapati. "Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial." Phytomedicine 105 (2022): 154334.
   View at Publisher | View at Google Scholar
8. Caruso, Salvatore, Diletta Mauro, Maria Cariola, Valentina Fava, Agnese Maria Chiara Rapisarda, and Antonio Cianci. "Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder." Gynecological Endocrinology 34, no. 2 (2018): 110-114.
   View at Publisher | View at Google Scholar